Lactobacillus spp. from the Human Gut Microbiota as a Therapeutic Tool in Controlling MRSA-Induced Sepsis

Area of Science:

• Microbiology
• Immunology
• Pharmacology

Background:

• Sepsis, an overreaction to infection, is a major global mortality cause.
• Antibiotic resistance necessitates alternative sepsis treatments beyond conventional antibiotics.
• The human gut microbiome is a promising area for novel therapeutic strategies.

Purpose of the Study:

• To investigate the potential of partially purified proteins from Lactobacillus spp. as an alternative therapeutic agent against Staphylococcus aureus-induced sepsis.
• To evaluate the efficacy of these proteins in controlling bacterial growth and protecting host immune cells.

Main Methods:

• Proteins were isolated from Lactobacillus spp. using lysis buffer, ammonium sulphate precipitation, and dialysis.
• Efficacy was assessed using cytotoxicity and cell viability assays (MTT, dye exclusion) on Staphylococcus aureus-infected blood samples.
• Statistical analysis (ANOVA) was employed to determine the impact of protein concentrations and demographic factors.

Main Results:

• A 1:8 and 1:10 Staphylococcus aureus-to-protein ratio demonstrated significant control and inhibition of bacterial growth.
• The addition of specific protein concentrations reduced cellular damage and protected systemic immune cells.
• Statistical analysis indicated protein efficacy was independent of age and gender in the tested samples.

Conclusions:

• Partially purified proteins from Lactobacillus spp. show potential as a novel therapeutic approach for managing Staphylococcus aureus sepsis.
• The gut microbiome represents a valuable resource for developing new strategies to combat sepsis and reduce inflammasome overactivation.
• This study provides a foundation for further research into microbiome-derived therapeutics for infectious diseases.